As of April 3, 2026, the American equity market is witnessing a historic "Great Rotation" that many analysts believe could define the latter half of the decade. For the first time in over a quarter-century, the valuation gap between the S&P 500 (INDEXSP:INX) and the Russell 2000 (INDEXRUSSELL:
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive technical breakout followed the announcement that Biogen (Nasdaq: BIIB) has entered into a definitive agreement to acquire the leader
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion in cash. The deal, valued at $41 per
SAN JOSE, CA – December 11, 2025 – In a pivotal move poised to redefine the landscape of semiconductor design and cybersecurity, Arteris, Inc. (NASDAQ: APLS), a leading provider of system IP for accelerating chiplet and System-on-Chip (SoC) creation, today announced its definitive agreement to acquire Cycuity, Inc., a pioneer in semiconductor cybersecurity assurance. This [...]
Apellis Pharmaceuticals exemplifies the GARP strategy with strong commercial growth, recent profitability, and a valuation attractive relative to biotech peers.
Discover Apellis Pharmaceuticals (APLS), an affordable growth stock with strong revenue growth, fair valuation, and solid financial health for investors.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
